Guidelines     MGP Ltd



Forthcoming guidance
 
Published guidance
 
Select guidance type:
Select Clinical speciality:

Date: from to

Search



Title Type Clinical speciality   Expected date   Last updated date
Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein NICE Technology Appraisal Cardiovascular Feb 2020 Nov 2020
Pembrolizumab for untreated metastatic or unresectable recurrent squamous cell head and neck cancer NICE Technology Appraisal Cancer Nov 2020 Sep 2020
Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer NICE Technology Appraisal Cancer Nov 2020 -
Antimicrobial prescribing: cefiderocol NICE Evidence summary Infection Dec 2020 Nov 2020
Liraglutide for managing overweight and obesity NICE Technology Appraisal Obesity Dec 2020 Nov 2020
mexiletine (Namuscla) SMC advice Neurology Dec 2020 Nov 2020
bempedoic acid (Nilemdo) SMC advice Genetic conditions Dec 2020 -
venetoclax (Venclyxto) SMC advice Cancer Dec 2020 Oct 2020
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia NICE Technology Appraisal Cancer Dec 2020 Nov 2020
Upadacitinib for treating severe rheumatoid arthritis NICE Technology Appraisal Musculoskeletal and joints Dec 2020 -
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders NICE Technology Appraisal Neurology Dec 2020 Oct 2020
Atezolizumab with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma NICE Technology Appraisal Cancer Dec 2020 -
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura NICE Technology Appraisal Haematological conditions Dec 2020 -
Diabetes in pregnancy: management from preconception to the postnatal period NICE Clinical Guideline Diabetes Dec 2020 Oct 2020
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (update) NICE Clinical Guideline Diabetes Dec 2020 Sep 2020
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) NICE Technology Appraisal Cancer Dec 2020 Oct 2020
Antimicrobial prescribing: delafloxacin NICE Evidence summary Infection Jan 2021 -
KTE-X19 for treating relapsed or refractory mantle cell lymphoma NICE Technology Appraisal Cancer Jan 2021 -
Encorafenib in dual or triple therapy for previously treated BRAF V600E mutation-positive metastatic colorectal cancer NICE Technology Appraisal Cancer Jan 2021 Nov 2020
Suspected neurological conditions NICE Quality Standard Neurology Jan 2021 Oct 2020
daratumumab (Darzalex) SMC advice Cancer Jan 2021 Nov 2020
entrectinib (Rozlytrek) SMC advice Cancer Jan 2021 -
fostamatinib (Tavlesse) SMC advice Haematological conditions Jan 2021 -
melatonin (Slenyto) SMC advice Neurology Jan 2021 Nov 2020
secukinumab (Cosentyx) SMC advice Musculoskeletal and joints Jan 2021 Nov 2020
brentuximab vedotin (Adcetris) SMC advice Cancer Jan 2021 Nov 2020
Selinexor with low-dose dexamethasone for treating refractory multiple myeloma NICE Technology Appraisal Cancer Jan 2021 -
Chronic pain: assessment and management NICE Clinical Guideline Pain Jan 2021 Sep 2020
Abortion care NICE Quality Standard Women's health Jan 2021 Nov 2020
Metreleptin for treating lipodystrophy NICE Technology Appraisal Skin and wound care Jan 2021 Nov 2020
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor NICE Technology Appraisal Cancer Jan 2021 Oct 2020
Crizanlizumab for preventing sickle cell crises in sickle cell disease NICE Technology Appraisal Haematological conditions Jan 2021 -
Acalabrutinib for untreated and treated chronic lymphocytic leukaemia NICE Technology Appraisal Cancer Jan 2021 -
Trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies NICE Technology Appraisal Cancer Jan 2021 -
Dupilumab for treating severe asthma NICE Technology Appraisal Respiratory Jan 2021 Oct 2020
Multiple myeloma - lenalidomide (maintenance, post autologous stem cell transplantation) NICE Technology Appraisal Cancer Jan 2021 Oct 2020
Dapagliflozin for treating heart failure with reduced ejection fraction NICE Technology Appraisal Cardiovascular Feb 2021 -
Mepolizumab for treating severe eosinophilic asthma NICE Technology Appraisal Respiratory Feb 2021 Nov 2020
ozanimod (Zeposia) SMC advice Neurology Feb 2021 Nov 2020
upadacitinib (Rinvoq) SMC advice Musculoskeletal and joints Feb 2021 -